STOCK TITAN
  1. Home
  2. News
  3. RVMD

Revolution Medicines Inc - RVMD STOCK NEWS

Welcome to our dedicated news page for Revolution Medicines (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revolution Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revolution Medicines's position in the market.

News
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
Rhea-AI Summary
Revolution Medicines, a clinical-stage oncology company, presented promising clinical data for RMC-6236 and RMC-6291 at AACR-NCI-EORTC and ESMO Meetings. The company also provided an update on its financial results and announced the expected close of the acquisition of EQRx, Inc. The clinical data showed significant anti-tumor activity for both drugs, supporting their advancement into late-stage development. The acquisition is expected to add approximately $1.1 billion in net cash proceeds. Revolution Medicines aims to revolutionize treatment for RAS-addicted cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
earnings
-
News
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
Rhea-AI Summary
Revolution Medicines, Inc. will report financial results for the third quarter 2023 on November 6, 2023, after market close. The senior management team will host a webcast to discuss the financial results and provide an update on corporate progress. A replay will be available on the company's website for at least 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences earnings
-
News
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
Rhea-AI Summary
Revolution Medicines announces promising anti-tumor and safety data for RMC-6236 in patients with lung cancer and pancreatic cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
Rhea-AI Summary
Revolution Medicines announces encouraging preliminary clinical data for RMC-6236 and RMC-6291
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.6%
Tags
clinical trial
-
News
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
Rhea-AI Summary
Revolution Medicines will present new clinical data for RMC-6236 and RMC-6291 at upcoming oncology conferences. Preliminary safety and pharmacokinetic profiles for RMC-6236 will be presented at the Triple Meeting. Additional antitumor activity data for RMC-6236 will be presented at ESMO. The company will also host an investor webcast to review the clinical data presentations and overall pipeline and strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
conferences clinical trial
-
News
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
Rhea-AI Summary
Revolution Medicines announces initiation of Phase 1/1b trial for RMC-9805, a KRASG12D(ON) Inhibitor for RAS-addicted cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
clinical trial
News
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
Rhea-AI Summary
Revolution Medicines, Inc. announces the publication of a research paper in Science, describing their tri-complex inhibitor approach to developing small molecules for RAS-addicted cancers. The paper discusses the creation of innovative small molecules that target mutant KRASG12C proteins, which are common causes of lung and colorectal cancers. The compounds showed promising results in preclinical studies, inhibiting oncogenic signaling and driving tumor regressions in human xenograft models. Revolution Medicines is currently evaluating their clinical candidate, RMC-6291, in a Phase 1/1b trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
News
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
earnings
-
News
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
conferences earnings
News
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
Rhea-AI Summary
Revolution Medicines plans to acquire EQRx in an all-stock transaction, adding over $1 billion in net cash to Revolution Medicines' balance sheet. The acquisition will enhance Revolution Medicines' efforts to develop RAS(ON) Inhibitor drugs for RAS-addicted cancers. The deal is subject to customary closing conditions and is expected to close in November 2023. The transaction reflects confidence in Revolution Medicines' ability to deploy capital effectively and maximize the potential clinical impact of its drug pipeline. Certain EQRx stockholders have entered into support and voting agreements. Revolution Medicines will focus on its RAS-focused assets and will not advance EQRx's R&D portfolio after the transaction closes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
acquisition
Stock RVMD logo
Revolution Medicines Inc

Nasdaq:RVMD

RVMD Rankings

#1106 Ranked by Market Cap
#2552 Ranked by Stock Gains
N/A Ranked by Dividends

RVMD Stock Data

5.94B
160.83M
2.46%
96.16%
7.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About RVMD

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.